Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KHK | P50053 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22754166 | 0.79 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1ADRB1MBTD1TP53BP1 | |
| SCHEMBL27606543 | 0.78 | ADRB1 (0.54) | ADRB1ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL17689751 | 0.77 | ADRB1 (0.43) | ADRB1ALDH1A1MAPTKHKSMN1; SMN2 | |
| SCHEMBL27606324 | 0.76 | ADRB1 (0.63) | ADRB1ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL10209402 | 0.75 | KHK (0.50) | L3MBTL3L3MBTL1ADRB1KHKHTR7 | |
| SCHEMBL14747897 | 0.75 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL21761919 | 0.75 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL18427059 | 0.75 | ADRB1 (0.39) | ADRB1SMN1; SMN2HTR7 | |
| SCHEMBL1911852 | 0.75 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1ALDH1A1MBTD1TP53BP1 | |
| SCHEMBL310165 | 0.74 | L3MBTL1 (0.60) | L3MBTL3L3MBTL1ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | disclosed |
| US-9963452-B2 | Methods, compounds, and compositions for inhibition of ROS | AUGUSTA PHARMACEUTICALS INC. (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | L3MBTL3 3797/4885L3MBTL1 3563/4885ADRB1 1388/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL3 3173/4885L3MBTL1 2990/4885ADRB1 1655/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | L3MBTL3 3147/4885L3MBTL1 2751/4885ADRB1 2766/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL3 3173/4885L3MBTL1 2990/4885ADRB1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.